AllerT: Phase IIb data

Data from 196 patients in the follow-up Phase IIb AN005T trial showed that 50 and 100 ug doses of subcutaneous AllerT each improved mean RSMS scores during the second birch pollen season (2014) following treatment, the primary endpoint, vs. placebo. Specifically, low- and high-dose AllerT improved mean RSMS scores by 21% and 18% during the 2014 season vs. placebo (p=0.02 and p=0.07, respectively). On secondary endpoints, low- and high-dose AllerT improved Mini-RQLQ scores by 21% and 20% (p=0.03 and p=0.05, respectively) and improved NNSS by 30% and 39% (p=0.014 and p=0.003, respectively) during the 2014 season compared to placebo. Data were presented at the American Academy of Allergy, Asthma and Immunology meeting in Houston.

All patients in the trial participated in the double-blind, placebo-controlled, European Phase IIb AN004T trial, which evaluated 5 subcutaneous injections of 50 and 100 ug AllerT over a 2-month period prior to the 2013 season. Patients did not receive further treatment in the AN005T study. ...